- Home
- About
- Resource Library
- Mental Health Disorders
- Agitation
- Anxiety Disorders
- Bipolar Disorder
- Cognition
- Depression
- Eating Disorders
- Personality Disorders
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Women’s Health
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Early Episode Psychosis
- Health Care Policy & Legislation
- Neuroscience
- Payer & Financing Models
- Quality Standards & Performance Measures
- Stigma
- Suicide Awareness
- Wellness
- Collections
- Featured
- Monthly Spotlight
- Psychopharmacology
- Learning Tracks
- Community Insights
- Community Podcast
- Disease Management & Support Tools
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Patient & Caregiver Resource Center
- PsychU Roleplay
- Psychiatric Scales
- PsychUSim
- Events
Live Event – Recognizing & Responding To Inadequately Treated MDD
About This Event
Live Event – Recognizing & Responding To Inadequately Treated MDD
In this presentation, the objectives are to:
- Discuss the burden of MDD on the individual and society
- Explore the negative impact of residual symptoms
- Identify patient and treatment characteristics associated with a poor treatment response
- Discuss strategies to optimize pharmacotherapy
Venue
Stone Creek Dining Company
13904 Town Center Blvd Ste 900
Noblesville, Indiana 46060 United States + Google Map317-770-1170 View Venue WebsiteFeaturing
-
Alex Matushek, PharmD, MBA (OPDC)
Clinical & Scientific Liaison
Alex Matushek, PharmD, MBA is an emploee for Otsuka Pharmaceutical Development & Commercialization, Inc.
Related Events
-
Joint Live Event – Major Depressive Disorder (MDD) in Chronic Kidney Disease (CKD)
July 12 6:30 pm to 8:30 pm -
Live Event – Importance Of Adherence To Outcomes In Schizophrenia & Bipolar Disorder
July 13 6:00 pm to 9:00 pm
Registration
PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients. NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.
Event Navigation
- « Virtual Event – The Impact of 2nd Generation Antipsychotic Side Effects on Functioning from a Schizophrenia Patient Perspective: A Global Patient Centered Study
- Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder »
Stay Connected:
- Resource Library